CG oncology Inc

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

ArriVent Biopharma Inc

Upstream Bio Inc

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY.

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 75.2% complete response rate in a phase 3 monotherapy study. Cretostimogene, an oncolytic immunotherapy, works by selectively replicating in cancer cells and encoding GM-CSF to activate the immune system. The market potential for cretostimogene is significant, targeting BCG-unresponsive NMIBC patients with a multi-billion dollar opportunity.

CG Oncology: Promising Data, But Looks Expensive

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint in the CORE-001 study – – Demonstrated 75.2% CR rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in Cretostimogene Monotherapy BOND-003 study – – Initiated and dosed first patient in Expanded Access Program for Cretostimogene Grenadenorepvec; Enrollment ongoing –  IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the second quarter ended June 30, 2024, and provided business updates.

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

CG Oncology's cretostimogene shows high potential to disrupt the NMIBC market with promising efficacy and safety data. The company is initially targeting high-risk NMIBC patients who no longer respond to the BCG vaccine, but intermediate-risk patients could bring the addressable market above 60,000. Cretostimogene is the company's only asset and there is likely to be significant competition, most likely from Johnson & Johnson.

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS).

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-Risk NMIBC (IR-NMIBC) Final Results from CORE-001 Phase 2 Clinical Trial of Cretostimogene in Combination with Pembrolizumab in BCG-Unresponsive HR-NMIBC will be presented at ASCO 2024 Completed Oversubscribed and Upsized $437 Million Initial Public Offering that Extends Expected Runway Through 2027 IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the first quarter ended March 31, 2024, and provided business updates.

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

CG Oncology, Inc. achieved positive results from its phase 3 BOND-003 study using cretostimogene for the treatment of high-risk BCG unresponsive NMIBC patients; Final data expected end of 2024.

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 2024.

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, will host a virtual investor event on Friday, May 3, 2024, at 4:30pm EDT.

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that an abstract with final results of CORE-001, its Phase 2 trial of cretostimogene in combination with pembrolizumab, will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, which will take place from May 31-June 4, 2024, at McCormick Place Convention Center, in Chicago, IL.

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session - - New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session -

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

iShares Nasdaq Biotechnology ETF

One way to find potentially winning stocks to buy in March, April, and throughout the year is to search for companies gaining more attention from Wall Street analysts.

How to Find Up-and-Coming Stocks to Buy Right Now

Kyverna Therapeutics Inc

Biotech businesses tend to be volatile after their initial public offerings. Kyverna Therapeutics raised more than twice what was initially expected.

Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?

Protara Therapeutics Inc

Protara Therapeutics is developing therapies for cancer and rare diseases, with a focus on non-muscle invasive bladder cancer and lymphangiomas.

Protara: A Bombed Out Biotech With A Very Positive Skew

Akoustis Technologies

Columbia Banking System

The insiders are buying these attractive stocks. With a bank, a tech, a penny stock, a dividend payer, and a pharmaceutical winner, there is something for all.

3 attractive stocks that insiders are buying

Adicet Bio, Inc.

Corbus Pharmaceuticals Holdings

Arcus Biosciences

Vera Therapeutics

As January wound to a close, the most notable insider purchases were in biopharma companies, particularly those with initial or secondary offerings of stock.

Insider Buying at These Biotechs Is Huge

IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares.

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

BrightSpring Health Services Inc

American Healthcare REIT Inc., Fortegra Group Inc. and Fractyle Health Inc. set proposed price ranges in their upcoming initial public offerings on Monday, after a mixed reception to two deals late last week.

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

Seven IPOs priced this past week, led by 3 that raised $100+ million. Four very small Chinese issuers also began trading in the US this past week, all raising $10 million or less.

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Biotech stocks have fallen about 1% so far this year.

Biotech's First IPO of 2024 Popped 96%. What It Means.

With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year's most highly anticipated IPOs. The company's lead drug targets a sizable addressable market (NMIBC) where there is an urgent need for safer, more widely available treatment options. The current standard of care treatment, the BCG vaccine, is in short supply and currently being rationed.

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq.

CG Oncology valued at $1.75 bln in strong market debut

Cancer drug company CG Oncology Inc. priced its initial public offering above its estimated range and added three million shares to the deal in a bullish sign ahead of its trading debut Thursday on the Nasdaq.

News for CG oncology Inc Stock (CGON)